Hospital operator HCA Healthcare (NYSE: HCA) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 3.6% year on year to $19.85 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ consensus estimates. Its GAAP profit of $7.27 per share was 7% above analysts’ consensus estimates.

For more on HCA Healthcare, read the full research report, available free.

Revenue growth

A company’s long-term revenue performance is one signal of its overall quality. Even a poor business can perform well for one or two quarters, but a high-quality one grows for years. Unfortunately, HCA Healthcare’s 6.3% annualized revenue growth over the last five years was mediocre. That result was underwhelming compared to the rest of the healthcare sector, but HCA Healthcare still has strengths.

Long-term growth matters most, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. HCA Healthcare’s annualized revenue growth of 6.3% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.

This quarter, HCA Healthcare reported modest year-on-year revenue growth of 3.6% but beat Wall Street’s consensus estimates by 3%.

Looking ahead, sell-side analysts expect revenue to grow 2.2% over the next 12 months, according to S&P, a deceleration versus the last two years. That underwhelming outlook indicates its products and services will face some demand headwinds. On the positive side, the company is performing well on other measures of financial health.

Operating margin

HCA Healthcare has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 16.4%.

Looking at the trend in its profitability, HCA Healthcare’s operating margin decreased by 1.8 percentage points over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings per share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth. For example, a company could inflate its revenue through excessive spending on advertising and promotions.

HCA Healthcare’s EPS grew at a compounded annual growth rate of 9% over the last five years, higher than its 6.3% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its operating margin didn’t improve.

Examining HCA Healthcare’s earnings quality can help explain its performance. A five-year view shows that HCA Healthcare has repurchased its stock, shrinking its share count by 33%. This indicates its EPS outperformed its revenue not because of increased operational efficiency but because of financial engineering, as buybacks boost per share earnings.

In Q3, HCA Healthcare reported EPS of $7.27, up from $6.96 in the same quarter last year. This result beat analysts’ consensus estimates by 7%. Over the next 12 months, Wall Street expects HCA Healthcare’s full-year EPS to grow 5.4% from $30.18 to $31.82, according to S&P.

Key takeaways from HCA Healthcare’s Q3 results

HCA Healthcare delivered a strong quarter, beating analysts’ consensus estimates for revenue and Wall Street’s EPS estimates. The Company now believes results will be in the upper end of its full year guidance range. Shares surged 5.7% to $491.76 immediately after the report.

When deciding whether to buy the stock, the latest quarter matters, but not nearly as much as longer-term fundamentals and valuation. Read the full research report here (it’s free).